Alexandra Kropotova
iBioAbout Alexandra Kropotova
Dr. Alexandra Kropotova, 53, has served as an independent director of iBio since October 2020. She is Chair of the Nominating & Corporate Governance Committee and a member of the Compensation Committee; she is standing for re‑election as a Class II director with a term through the 2028 Annual Meeting if elected . Kropotova is Executive Vice President and Chief Medical Officer at SAb Biotherapeutics; previously she led global clinical development at Teva and held senior R&D and medical affairs roles at Sanofi and Pfizer. She holds an MBA from Ohio University and an MD in Internal Medicine from Vladivostok State Medical University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Teva Pharmaceuticals | Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area | Prior to joining SAb; not dated precisely | Led design and execution of global clinical programs, largely biologics |
| Sanofi | VP and AVP roles across Immuno-Inflammation; Strategy & Strategic Planning Head, North American Medical Affairs; Senior Medical Director, Respiratory/Allergy/Anti‑Infectives | 2007–2016 | Led immuno‑inflammation R&D and medical affairs programs |
| Pfizer | Director & Head, Global Clinical Respiratory and Analgesics | 2002–2007 | Led global clinical respiratory/analgesics |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| SAb Biotherapeutics (public) | Executive Vice President & Chief Medical Officer | Current | Leads strategy and execution of polyclonal antibody portfolio |
Board Governance
- Class II director nominee in 2025; term to 2028 if re‑elected .
- Independence: Board determined all directors except CEO Martin Brenner are independent under Nasdaq rules; Kropotova is independent and all current Audit, Compensation, and Nominating & Corporate Governance committee members are independent .
- Meetings/attendance FY2025: Board met 6 times; Audit 6; Compensation 4; Nominating & Corporate Governance 5; all directors attended ≥75% of their meetings .
- Risk oversight: Nominating & Corporate Governance oversees board structure/performance, CSR/sustainability, and governance practices; Compensation oversees compensation policies; Audit oversees financial reporting, internal controls, ERM/cybersecurity .
- Committee memberships FY2025: Chair, Nominating & Corporate Governance; Member, Compensation .
| Committee | Role | FY2025 Meetings |
|---|---|---|
| Nominating & Corporate Governance | Chair | 5 |
| Compensation | Member | 4 |
Fixed Compensation
| Metric | FY2025 |
|---|---|
| Fees Earned or Paid in Cash ($) | $54,141 |
| Stock Awards ($) | $46,205 (see footnote re: option award fair value) |
| Option Awards ($) | $— (fair value amounts described as option awards per footnote) |
| Total ($) | $100,346 |
Director fee schedule (policy amounts for FY2025):
| Service | Member Annual Retainer ($) | Chair Annual Retainer ($) |
|---|---|---|
| Board | 40,000 | 35,000 |
| Audit Committee | 10,000 | 20,000 |
| Compensation Committee | 7,500 | 15,000 |
| Nominating & Corporate Governance Committee | 5,000 | 10,000 |
Notes: Retainers paid quarterly and prorated for service changes; new directors receive an initial option grant with 36‑month vesting .
Performance Compensation
| Award Detail | FY2025 |
|---|---|
| Options awarded (shares) | 18,900 |
| Grant date fair value (ASC 718) | $46,205 (footnote indicates this column reflects option award fair value) |
| Options outstanding (as of June 30, 2025) | 19,318 total; 11,443 vested |
| Initial director grant policy | One‑time grant of 12,600 options vesting over 36 months upon initial election |
| Performance metrics tied to director compensation | None disclosed (director equity awards are not performance‑metric based) |
Other Directorships & Interlocks
| Company | Role | Committee Roles | Interlocks/Conflicts |
|---|---|---|---|
| None disclosed | — | — | No other public company directorships disclosed for Dr. Kropotova in the proxy |
Expertise & Qualifications
- Biopharma executive with end‑to‑end expertise across clinical development, translational medicine, and medical affairs in respiratory, inflammatory, autoimmune indications .
- Senior leadership experience across Teva, Sanofi, Pfizer; current CMO role at SAb Biotherapeutics .
- Education: MBA (Ohio University) and MD (Vladivostok State Medical University) .
- Governance capability evidenced by chairing Nominating & Corporate Governance amid board refreshment and committee independence requirements .
Equity Ownership
| Holder | Beneficial Ownership (shares) | Ownership % of 20,254,599 SO | Composition |
|---|---|---|---|
| Alexandra Kropotova | 19,318 | <1% (asterisk denotes less than 1%) | 19,318 options vested/will vest within 60 days |
| Options breakdown (as of June 30, 2025) | 19,318 total | — | 11,443 vested; 7,875 unvested |
Shares outstanding: 20,254,599 as of October 3, 2025 . Company policy prohibits hedging and pledging of company securities by directors, officers, and employees .
Governance Assessment
- Board effectiveness: As Nominating & Corporate Governance Chair, Kropotova presides over board evaluations, director nominations, and governance framework updates; committee activity (5 meetings in FY2025) indicates engagement . Her Compensation Committee service supports oversight of pay structures and the engagement of an independent consultant (Aon) in FY2025, enhancing pay governance .
- Independence and attendance: Affirmatively determined independent under Nasdaq rules; met at least the 75% attendance threshold (Board and committee meetings) — both support investor confidence in oversight quality.
- Pay & alignment signals: Director compensation mix features cash retainers and option grants; FY2025 cash ($54,141) versus option grant fair value ($46,205) indicates balanced cash/equity mix . However, beneficial ownership is low (<1%) with holdings comprised of options rather than common shares, which may be perceived as modest “skin‑in‑the‑game” alignment for some investors .
- Conflicts/related parties: Audit Committee reviews related‑party transactions; no related‑party transactions involving Dr. Kropotova are indicated in the proxy excerpts reviewed. Restrictions on hedging/pledging reduce alignment risks .
- Red flags: None evident in the proxy excerpts (no low attendance, no pledging, no related‑party transactions disclosed for her). Potential watch item is time commitment given her full‑time CMO role at SAb Biotherapeutics; no business ties between SAb and iBio are disclosed in the proxy excerpts reviewed .